Investment of $29.9M for isotope production facility in Quebec

ISOLOGIC Innovative Radiopharmaceuticals is investing $29.9 million to support the growth of the radiopharmaceutical industry and to reinforce its critical role in the field of nuclear medicine and the Canadian medical isotope supply chain as part of Quebec’s life sciences ecosystem.

Approximately $19 million will be devoted to the expansion and modernization of the Lachine borough site, and $11 million will be used to purchase state of the art equipment which includes an 18 MeV cyclotron which will be operational from the first quarter of 2026. This investment will help add redundancy to the supply chain and meet the growing demand for critically important PET diagnostic radioisotopes in both Quebec and across Canada.

“This investment shows ISOLOGIC’s commitment to patients and physicians in Québec and throughout Canada,” says André Gagnon, president of ISOLOGIC Radiopharmaceutiques Novateurs. “We are proud to support Canadian physicians in their diagnostic and therapeutic mission by providing access to highly effective and emerging radiopharmaceutical products used worldwide.”

Driven by an aging population and the rising incidence of many cancers, there is growing use and demand for PET diagnostic agents throughout Canada, as well as renewed medical interest in radioligand therapies for cancer treatment. The new site will ensure an uninterrupted local supply of PET radioisotopes for many years to come, and further position Québec as a radiopharmaceutical leader in supporting the Canadian market.